Quartalsergebnisse (Earnings) für Charles River Laboratories

gurufocus.com2026-02-18 16:06:00

Charles River Laboratories International Inc (CRL) Q4 2025 Earnings Call Highlights: Navigating Revenue Declines and Strategic Acquisitions

Fourth Quarter Revenue: $994.2 million, a 2.6% decline on an organic basis.Full Year Revenue: $4.02 billion, with an organic revenue decrease of 1.6%.Operating

seekingalpha.com2026-02-18 13:54:59

Charles River Laboratories International, Inc. (CRL) Q4 2025 Earnings Call Transcript

seekingalpha.com2026-02-18 11:20:56

Charles River Laboratories Q4 Review: Approaching A Bottom

zacks.com2026-02-18 10:31:13

Here's What Key Metrics Tell Us About Charles River (CRL) Q4 Earnings

Although the revenue and EPS for Charles River (CRL) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

zacks.com2026-02-18 09:55:27

CRL Stock Down Despite Q4 Earnings & Revenue Beat, Margins Rise

Charles River tops Q4 earnings and revenue estimates as margins expand, but shares dip, and organic growth declines across all segments.

zacks.com2026-02-18 09:11:15

Charles River Laboratories (CRL) Q4 Earnings and Revenues Surpass Estimates

Charles River Laboratories (CRL) came out with quarterly earnings of $2.39 per share, beating the Zacks Consensus Estimate of $2.33 per share. This compares to earnings of $2.66 per share a year ago.

reuters.com2026-02-18 07:54:24

Charles River forecasts upbeat 2026 profit on improved demand for drug development services

Contract drug developer Charles River Laboratories on Wednesday forecast annual profit above Wall Street estimates, betting on an improvement in demand for its drug discovery and development services from biotech clients.

businesswire.com2026-02-18 07:01:00

Charles River Laboratories Announces Executive Appointments

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Announces Executive Appointments.

businesswire.com2026-02-18 07:00:00

Charles River Laboratories Announces Fourth-Quarter and Full-Year 2025 Results and Provides 2026 Guidance

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Announces Fourth-Quarter and Full-Year 2025 Results and Provides 2026 Guidance.

seekingalpha.com2026-02-17 15:15:33

Aquestive Therapeutics: Biology Validated, Packaging Pending - A Forensic Analysis Of The Anaphylm CRL

EPS (USD)

Umsatz (USD)

Revisionen der Gewinnschätzungen